Omitted guideline-recommended sectors drove local failure after sacral SBRT
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Experts propose selecting radiotherapy–drug regimens using efficacy, scheduling, late toxicity, biomarkers, and patient-reported outcomes rather than maximum tolerated dose alone.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Adaptation would have improved organ sparing or target coverage in 46% of fractions, with a median workflow time of 61.9 minutes.
Different carbon-ion RBE models can assign substantially different biological doses to the same absorbed-dose distribution, requiring context-specific translation.
A 1 mm symmetric MLC closing reduced minimum GTV dose by 25%, while translations caused cumulative target undercoverage.
A 1 cm high-density bolus overcame 6 MV photon build-up, but a 2 cm air gap reduced small-field skin dose by 21%.
TLD-100 over-responded below 7 Gy/s and under-responded above 300 Gy/s, despite remaining dose-independent from 3 to 18 Gy.
A dual-input MRI–CT model segmented 25 neurological organs with a median Dice score of 0.80 and surface Dice of 0.84.
Pelvic insufficiency fractures occurred in 29.2% of patients, with postmenopause and elevated baseline t-PINP independently predicting risk.
A structured sleep protocol enabled sedation-free delivery in 96.4% of radiotherapy fractions among children younger than four years.
An MTV threshold of 50 mL identified patients with poorer survival who appeared to benefit from combined-modality treatment.
Proton therapy produced greater CT-detected lung changes than photons despite lower lung dose and no increase in clinical pulmonary toxicity.
Two-year invasive recurrence fell from 27.5% to 5.5% with dose escalation, without higher grade 2 or greater toxicity.
Only 33% of statements reached consensus, but experts agreed on multimodality imaging, eligible lesions, and daily image guidance.